Integra LifeSciences Holdings Co. Forecasted to Earn FY2022 Earnings of $3.30 Per Share (NASDAQ:IART)

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Rating) – Investment analysts at Oppenheimer boosted their FY2022 EPS estimates for shares of Integra LifeSciences in a research note issued on Wednesday, April 27th. Oppenheimer analyst S. Lichtman now forecasts that the life sciences company will earn $3.30 per share for the year, up from their prior forecast of $3.28.

Integra LifeSciences (NASDAQ:IARTGet Rating) last announced its earnings results on Wednesday, April 27th. The life sciences company reported $0.74 earnings per share for the quarter, beating the consensus estimate of $0.68 by $0.06. The company had revenue of $376.60 million during the quarter, compared to the consensus estimate of $362.19 million. Integra LifeSciences had a return on equity of 16.84% and a net margin of 10.04%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the firm earned $0.69 earnings per share.

A number of other equities research analysts have also recently weighed in on the company. Piper Sandler cut their price target on Integra LifeSciences from $72.00 to $66.00 in a report on Wednesday, February 23rd. Truist Financial lowered Integra LifeSciences from a “buy” rating to a “hold” rating and decreased their price target for the company from $72.00 to $71.00 in a research report on Wednesday, April 13th. Bank of America increased their price target on Integra LifeSciences from $55.00 to $65.00 and gave the company an “underperform” rating in a research report on Tuesday, January 18th. Finally, StockNews.com raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $73.33.

Shares of IART stock opened at $61.16 on Monday. The company has a quick ratio of 2.46, a current ratio of 3.39 and a debt-to-equity ratio of 0.89. The business has a 50 day moving average of $64.49 and a two-hundred day moving average of $66.15. Integra LifeSciences has a 52 week low of $59.78 and a 52 week high of $76.70. The company has a market cap of $5.08 billion, a P/E ratio of 33.24, a PEG ratio of 1.97 and a beta of 1.14.

Institutional investors have recently made changes to their positions in the stock. CIBC Asset Management Inc grew its stake in Integra LifeSciences by 4.7% in the fourth quarter. CIBC Asset Management Inc now owns 3,558 shares of the life sciences company’s stock valued at $238,000 after acquiring an additional 160 shares during the period. Advisor Group Holdings Inc. raised its stake in Integra LifeSciences by 2.4% in the third quarter. Advisor Group Holdings Inc. now owns 7,376 shares of the life sciences company’s stock valued at $506,000 after buying an additional 175 shares during the period. State of Michigan Retirement System grew its position in shares of Integra LifeSciences by 1.1% in the fourth quarter. State of Michigan Retirement System now owns 18,466 shares of the life sciences company’s stock valued at $1,237,000 after purchasing an additional 200 shares during the last quarter. NorthCrest Asset Manangement LLC grew its position in shares of Integra LifeSciences by 1.5% in the first quarter. NorthCrest Asset Manangement LLC now owns 13,800 shares of the life sciences company’s stock valued at $887,000 after purchasing an additional 200 shares during the last quarter. Finally, Campbell Newman Asset Management Inc. grew its position in shares of Integra LifeSciences by 1.9% in the first quarter. Campbell Newman Asset Management Inc. now owns 12,743 shares of the life sciences company’s stock valued at $819,000 after purchasing an additional 243 shares during the last quarter. 90.98% of the stock is owned by institutional investors and hedge funds.

In other news, major shareholder Tru St Partnership, L.P. sold 75,000 shares of the business’s stock in a transaction on Wednesday, February 9th. The stock was sold at an average price of $65.82, for a total transaction of $4,936,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Glenn Coleman sold 6,268 shares of the business’s stock in a transaction on Monday, April 4th. The stock was sold at an average price of $66.04, for a total value of $413,938.72. Following the sale, the chief operating officer now owns 41,288 shares of the company’s stock, valued at approximately $2,726,659.52. The disclosure for this sale can be found here. Insiders have sold a total of 231,268 shares of company stock valued at $15,050,939 in the last 90 days. 4.20% of the stock is owned by corporate insiders.

Integra LifeSciences Company Profile (Get Rating)

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services.

Featured Stories

Earnings History and Estimates for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.